TheraRadar
← Back
Data updated: Jun 28, 2026

INSMED

Pharma
RespiratoryInfectious DiseaseCardiovascular Execution: Good

INSMED is a pharmaceutical company focused on Respiratory, Infectious Disease, Cardiovascular. Key products include ARIKAYCE KIT.

2005
Since
3
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2025)
1 Novel 1 First-in-Class 1 Priority Review
See 1 novel approval →
2025 BRINSUPRI (BRENSOCATIB) First-in-Class · Priority Review

INSMED at a Glance

  • Fast trial execution (16 months median completion)

INSMED's Key Drugs

INSMED's core commercial portfolio centers on ARIKAYCE KIT, BRINSUPRI, spanning Respiratory and Infectious Disease — its most strategically important drugs approved in the last 15 years.

ARIKAYCE KIT
Infectious Disease

Bacterial Septicemia

Ribosome Approved 2018
BRINSUPRI
Respiratory

Bronchiectasis

DPP1 Approved 2025

INSMED's Recent FDA Approvals

INSMED secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BRINSUPRI NDA
2025-08-12
brensocatib
Bronchiectasis

INSMED's Therapeutic Areas

INSMED's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 39%
0 drugs Phase 3: 5 Phase 2: 8 Phase 1: 1
Infectious Disease 29%
1 drugs Phase 3: 5 Phase 2: 1
Cardiovascular 23%
0 drugs Phase 3: 3 Phase 2: 5
Dermatology 6%
1 drugs
Gastroenterology 2%
0 drugs Phase 1: 2

INSMED Pipeline Snapshot

INSMED has 30 active clinical programs from ClinicalTrials.gov — 13 Phase 3, 14 Phase 2 and 3 Phase 1.

13
Phase 3
14
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ARIKAYCE KIT leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 7/10 completed
  • • Speed: 16 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges